DNA repair mechanisms in cancer development and therapy

Frontiers in Genetics

Volumn 6, Issue APR, 2015, Pages

  Torgovnick, Alessandro ^a   Schumacher, Björn ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Aging; Ataxia telangiectasia; Cancer therapy; DNA repair; Fanconi anemia; Genome instability; Progeroid syndromes; Xeroderma pigmentosum

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL NUCLEUS DNA; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; COPPER TRANSPORTER 1; CYCLINE; DEOXYCYTIDINE TRIPHOSPHATE; GLUTATHIONE; HISTONE H2AX; MAMMALIAN TARGET OF RAPAMYCIN; MEIOTIC RECOMBINATION PROTEIN 11; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NUCLEOSIDE ANALOG; ORGANIC CATION TRANSPORTER; PARP1 INHIBITOR; PROTEIN MSH2; PROTEIN MSH3; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; RNA POLYMERASE II; THYMIDINE KINASE 1; TRANSCRIPTION FACTOR IIH; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATAXIA TELANGIECTASIA; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE CHECKPOINT; CHEMORADIOTHERAPY; CHROMOSOME ABERRATION; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DNA REPAIR; FANCONI ANEMIA; GENETIC DISORDER; HUMAN; MALIGNANT TRANSFORMATION; MISMATCH REPAIR; MUTATION; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE; XERODERMA PIGMENTOSUM;

EID: 84940047092     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2015.00157     Document Type: Review

References (171)

1. Aas, P. A., Otterlei, M., Falnes, P. O., Vågbø, C. B., Skorpen, F., Akbari, M., et al. (2003). Human and bacterial oxidative demethylases repair alkylation damage in both RNA and DNA. Nature 421, 859-863. doi: 10.1038/nature01363.
2. Adamo, A., Collis, S. J., Adelman, C. A., Silva, N., Horejsi, Z., Ward, J. D., et al. (2010). Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. Mol. Cell 39, 25-35. doi: 10.1016/j.molcel.2010.06.026.
3. Alexanian, R., Bergsagel, D. E., Migliore, P. J., Vaughn, W. K., and Howe, C. D. (1967). Melphalan therapy for plasma cell myeloma. Blood 31, 1-10.
4. Allen, C., Borak, T. B., Tsujii, H., and Nickoloff, J. A. (2011). Heavy charged particle radiobiology: using enhanced biological effectiveness and improved beam focusing to advance cancer therapy. Mutat. Res. 711, 150-157. doi: 10.1016/j.mrfmmm.2011.02.012.
5. Arora, S., Kothandapani, A., Tillison, K., Kalman-Maltese, V., and Patrick, S. M. (2010). Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair. 9, 745-753. doi: 10.1016/j.dnarep.2010.03.010.
6. Bakkenist, C. J., and Kastan, M. B. (2003). DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506. doi: 10.1038/nature01368.
7. Bartek, J., and Lukas, J. (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429. doi: 10.1016/S1535-6108(03)00110-7.
8. Baskar, R., Lee, K. A., Yeo, R., and Yeoh, K.-W. (2012). Cancer and radiation therapy: current advances and future directions. Int. J. Med. Sci. 9, 193-199. doi: 10.7150/ijms.3635.
9. Begg, A. C., Stewart, F. A., and Vens, C. (2011). Strategies to improve radiotherapy with targeted drugs. 11, 239-253. doi: 10.1038/nrc3007.
10. Bonate, P. L., Arthaud, L., Cantrell, W. R., Stephenson, K., Secrist, J. A., and Weitman, S. (2006). Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat. Rev. Drug Discov. 5, 855-863. doi: 10.1038/nrd2055.
11. Bootsma, D., Kraemer, K. H., Cleaver, J. E., and Hoeijmakers, J. H. J. (2001). "Nucleotide excision repair syndromes: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy," in The Metabolic and Molecular Bases of Inherited Disease, 8th Edn, eds C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle, B. Childs, K. W. Kinzler, et al. (New York, NY: McGraw-Hill), 677-704.
12. Brooks, P. J., Marietta, C., and Goldman, D. (1996). DNA mismatch repair and DNA methylation in adult brain neurons. J. Neurosci. 16, 939-945.
13. Brown, E. J., and Baltimore, D. (2000). ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14, 397-402. doi: 10.1101/gad.14.4.397.
14. Bryant, H. E., Petermann, E., Schultz, N., Jemth, A.-S., Loseva, O., Issaeva, N., et al. (2009). PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 28, 2601-2615. doi: 10.1038/emboj.2009.206.
15. Burger, H., Loos, W. J., Eechoute, K., Verweij, J., Mathijssen, R. H. J., and Wiemer, E. A. C. (2011). Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist. Updat. 14, 22-34. doi: 10.1016/j.drup.2010.12.002.
16. Caestecker, K. W., and Van de Walle, G. R. (2013). The role of BRCA1 in DNA double-strand repair Past and present. Exp. Cell Res. 319, 575-587. doi: 10.1016/j.yexcr.2012.11.013.
17. Cerbinskaite, A., Mukhopadhyay, A., Plummer, E. R., Curtin, N. J., and Edmondson, R. J. (2012). Defective homologous recombination in human cancers. Cancer Treat. Rev. 38, 89-100. doi: 10.1016/j.ctrv.2011.04.015.
18. Chambon, P., Ramuz, M., and Doly, J. (1964). Relation between soluble DNA-dependent RNA polymerase and "aggregate" RNA polymerase. Biochem. Biophys. Res. Commun. 21, 156-161. doi: 10.1016/0006-291X(65)90102-6.
19. Chan, J. K., Loizzi, V., Manetta, A., and Berman, M. L. (2003). Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecol. Oncol. 92, 368-371. doi: 10.1016/j.ygyno.2003.09.017.
20. Ciccia, A., and Elledge, S. J. (2010). The DNA damage response: making it safe to play with knives. Mol. Cell 40, 179-204. doi: 10.1016/j.molcel.2010.09.019.
21. Cimprich, K. A., and Cortez, D. (2008). ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 9, 616-627. doi: 10.1038/nrm2450.
22. Clarke, M. L., Mackey, J. R., Baldwin, S. A., Young, J. D., and Cass, C. E. (2001). The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat. Res. 112, 27-47. doi: 10.1007/978-1-4615-1173-1_2.
23. Cleaver, J. E. (1968). Defective repair replication of DNA in xeroderma pigmentosum. Nature 218, 652-656. doi: 10.1038/218652a0.
24. Cleaver, J. E. (2005). Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat. Rev. Cancer 5, 564-573. doi: 10.1038/nrc1652.
25. Crossan, G. P., van der Weyden, L., Rosado, I. V., Langevin, F., Gaillard, P.-H. L., et al. (2011). Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. Nat. Genet. 43, 147-152. doi: 10.1038/ng.752.
26. Curtin, N. J. (2012). DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 12, 801-817. doi: 10.1038/nrc3399.
27. Damia, G., Filiberti, L., Vikhanskaya, F., Carrassa, L., Taya, Y., D'incalci, M., et al. (2000). Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 3, 10-16. doi: 10.1038/sj/neo/7900122.
28. Dasari, S., and Tchounwou, P. B. (2014). Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 740, 364-378. doi: 10.1016/j.ejphar.2014.07.025.
29. Day, R. S., Ziolkowski, C. H., Scudiero, D. A., Meyer, S. A., Lubiniecki, A. S., Girardi, A. J., et al. (1980). Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature 288, 724-727. doi: 10.1038/288724a0.
30. Deans, A. J., and West, S. C. (2011). DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 11, 467-480. doi: 10.1038/nrc3088.
31. De Bont, R., and van Larebeke, N. (2004). Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis 19, 169-185. doi: 10.1093/mutage/geh025.
32. de Klein, A., Muijtjens, M., van Os, R., Verhoeven, Y., Smit, B., Carr, A. M., et al. (2000). Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr. Biol. 10, 479-482. doi: 10.1016/S0960-9822(00)00447-4.
33. de Laat, W. L., Appeldoorn, E., Sugasawa, K., Weterings, E., Jaspers, N. G. J., and Hoeijmakers, J. H. J. (1998). DNA-binding polarity of human replication protein A positions nucleases in nucleotide excision repair. Genes Dev. 12, 2598-2609. doi: 10.1101/gad.12.16.2598.
34. De Weerd-Kastelein, E. A., Keijzer, W., and Bootsma, D. (1972). Genetic Heterogeneity of xeroderma pigmentosum demonstrated by somatic cell hybridization. Nat. New Biol. 238, 80-83. doi: 10.1038/newbio238080a0.
35. Delaney, G., Jacob, S., Featherstone, C., and Barton, M. (2005). The role of radiotherapy in cancer treatment. Cancer 104, 1129-1137. doi: 10.1002/cncr.21324.
36. Diderich, K., Alanazi, M., and Hoeijmakers, J. H. J. (2011). Premature aging and cancer in nucleotide excision repair-disorders. DNA Repair. 10, 772-780. doi: 10.1016/j.dnarep.2011.04.025.
37. Elvers, I., Johansson, F., Groth, P., Erixon, K., and Helleday, T. (2011). UV stalled replication forks restart by re-priming in human fibroblasts. Nucleic Acids Res. 39, 7049-7057. doi: 10.1093/nar/gkr420.
38. Emadi, A., Jones, R. J., and Brodsky, R. A. (2009). Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol. 6, 638-647. doi: 10.1038/nrclinonc.2009.146.
39. Evans, E. (1997). Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J. 16, 6559-6573. doi: 10.1093/emboj/16.21.6559.
40. Ewald, B., Sampath, D., and Plunkett, W. (2008). Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 27, 6522-6537. doi: 10.1038/onc.2008.316.
41. Fagbemi, A. F., Orelli, B., and Schärer, O. D. (2011). Regulation of endonuclease activity in human nucleotide excision repair. DNA Repair. 10, 722-729. doi: 10.1016/j.dnarep.2011.04.022.
42. Ferry, K. V., Hamilton, T. C., and Johnson, S. W. (2000). Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol. 60, 1305-1313. doi: 10.1016/S0006-2952(00)00441-X.
43. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehmé, A., et al. (1996). The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56, 4881-4886.
44. Fitch, M. E., Cross, I. V., Turner, S. J., Adimoolam, S., Lin, C. X., Williams, K. G., et al. (2003). The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. DNA Repair. 2, 819-826. doi: 10.1016/S1568-7864(03)00066-1.
45. Fu, D., Calvo, J. A., and Samson, L. D. (2012). Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat. Rev. Cancer 12, 104-120. doi: 10.1038/nrc3185.
46. Furgason, J. M., and Bahassi el, M. (2013). Targeting DNA repair mechanisms in cancer. Pharmacol. Ther. 137, 298-308. doi: 10.1016/j.pharmthera.2012.10.009.
47. Galanski, M. (2006). Recent developments in the field of anticancer platinum complexes. Recent. Pat. Anticancer Drug Discov. 1, 285-295. doi: 10.2174/157489206777442287.
48. Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., et al. (2011). Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883. doi: 10.1038/onc.2011.384.
49. Galmarini, C. M., Mackey, J. R., and Dumontet, C. (2002). Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 3, 415-424. doi: 10.1016/S1470-2045(02)00788-X.
50. Genini, D., Adachi, S., Chao, Q., Rose, D. W., Carrera, C. J., Cottam, H. B., et al. (2000). Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96, 3537-3543.
51. Gnewuch, C. T., and Sosnovsky, G. (1997). A critical appraisal of the evolution of N-Nitrosoureas as anticancer drugs. Chem. Rev. 97, 829-1014. doi: 10.1021/cr941192h.
52. Guillotin, D., and Martin, S. A. (2014). Exploiting DNA mismatch repair deficiency as a therapeutic strategy. Exp. Cell Res. 329, 110-115. doi: 10.1016/j.yexcr.2014.07.004.
53. Hakem, R., de la Pompa, J. L., Sirard, C., Mo, R., Woo, M., Hakem, A., et al. (1996). The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85, 1009-1023. doi: 10.1016/S0092-8674(00)81302-1.
54. Hall, E. J., and Giaccia, A. J. (2011). Radiobiology for the Radiologist, 7th Edn. Philadelphia: Lipincott William & Wilkin.
55. Hanawalt, P. C., and Spivak, G. (2008). Transcription-coupled DNA repair: two decades of progress and surprises. Nat. Rev. Mol. Cell Biol. 9, 958-970. doi: 10.1038/nrm2549.
56. Harrap, K. R. (1985). Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. 12(Suppl. A), 21-33. doi: 10.1016/0305-7372(85)90015-5.
57. Haut, A., Abbott, W. S., Wintrobe, M. M., and Cartwright, G. E. (1961). Busulfan in the treatment of chronic myelocytic leukemia. The effect of long term intermittent therapy. Blood 17, 1-19.
58. Hebra, F., and Kaposi, M. (1874). On diseases of the skin including exanthemata. New Sydenham Soc. 61, 252-258.
59. Helleday, T., Lo, J., Vangent, D., and Engelward, B. (2007). DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair. 6, 923-935. doi: 10.1016/j.dnarep.2007.02.006.
60. Hersh, E. M., O'Day, S. J., Powderly, J., Khan, K. D., Pavlick, A. C., Cranmer, L. D., et al. (2011). A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest. New Drugs 29, 489-498. doi: 10.1007/s10637-009-9376-8.
61. Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C., et al. (1990). Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res. 50, 4417-4422.
62. Holzer, A. K., Manorek, G. H., and Howell, S. B. (2006). Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol. 70, 1390-1394. doi: 10.1124/mol.106.022624.
63. Hsieh, P., and Yamane, K. (2008). DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech. Ageing Dev. 129, 391-407. doi: 10.1016/j.mad.2008.02.012.
64. Huang, P., Chubb, S., and Plunkett, W. (1990). Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J. Biol. Chem. 265, 16617-16625.
65. Huen, M. S. Y., Sy, S. M. H., and Chen, J. (2010). BRCA1 and its toolbox for the maintenance of genome integrity. Nat. Rev. Mol. Cell Biol. 11, 138-148. doi: 10.1038/nrm2831.
66. Iyama, T., and Wilson, D. M. III. (2013). DNA repair mechanisms in dividing and non-dividing cells. DNA Repair. 12, 620-636. doi: 10.1016/j.dnarep.2013.04.015.
67. Jackson, S. P., and Bartek, J. (2009). The DNA-damage response in human biology and disease. Nature 461, 1071-1078. doi: 10.1038/nature08467.
68. Jensen, R. B., Carreira, A., and Kowalczykowski, S. C. (2010). Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467, 678-683. doi: 10.1038/nature09399.
69. Jiricny, J. (2006). The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 7, 335-346. doi: 10.1038/nrm1907.
70. Johnson, S. A. (2001). Nucleoside analogues in the treatment of haematological malignancies. Expert Opin. Pharmacother. 2, 929-943. doi: 10.1517/14656566.2.6.929.
71. Jordheim, L. P., and Dumontet, C. (2007). Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim. Biophys. Acta 1776, 138-159. doi: 10.1016/j.bbcan.2007.07.004.
72. Jordheim, L. P., Durantel, D., Zoulim, F., and Dumontet, C. (2013). Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat. Rev. Drug Discov. 12, 447-464. doi: 10.1038/nrd4010.
73. Jung, Y., and Lippard, S. J. (2007). Direct cellular responses to platinum-induced DNA damage. Chem. Rev. 107, 1387-1407. doi: 10.1021/cr068207j.
74. Kaina, B., Christmann, M., Naumann, S., and Roos, W. P. (2007). MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair. 6, 1079-1099. doi: 10.1016/j.dnarep.2007.03.008.
75. Kelland, L. (2007a). Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Expert Opin. Investig. Drugs 16, 1009-1021. doi: 10.1517/13543784.16.7.1009.
76. Kelland, L. (2007b). The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584. doi: 10.1038/nrc2167.
77. Kim, Y.-J., and Wilson, D. M. (2011). Overview of base excision repair biochemistry. Curr. Mol. Pharmacol. 5, 3-13. doi: 10.2174/1874467211205010003.
78. Klapacz, J., Meira, L. B., Luchetti, D. G., Calvo, J. A., Bronson, R. T., Edelmann, W., et al. (2009). O6-methylguanine-induced cell death involves exonuclease 1 as well as DNA mismatch recognition in vivo. Proc. Natl. Acad. Sci. U.S.A. 106, 576-581. doi: 10.1073/pnas.0811991106.
79. Kondo, N., Takahashi, A., Ono, K., and Ohnishi, T. (2010). DNA damage induced by alkylating agents and repair pathways. J. Nucleic Acids 2010, 543531. doi: 10.4061/2010/543531.
80. Koonin, E. V., Altschul, S. F., and Bork, P. (1996). BRCA1 protein products... Functional motifs... Nat. Genet. 13, 266-268. doi: 10.1038/ng0796-266.
81. Kottemann, M. C., and Smogorzewska, A. (2013). Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 493, 356-363. doi: 10.1038/nature11863.
82. Kozlov, S. V., Graham, M. E., Peng, C., Chen, P., Robinson, P. J., and Lavin, M. F. (2006). Involvement of novel autophosphorylation sites in ATM activation. EMBO J. 25, 3504-3514. doi: 10.1038/sj.emboj.7601231.
83. Köberle, B., Masters, J. R., Hartley, J. A., and Wood, R. D. (1999). Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr. Biol. 9, 273-276. doi: 10.1016/S0960-9822(99)80118-3.
84. Köberle, B., Tomicic, M. T., Usanova, S., and Kaina, B. (2010). Cisplatin resistance: preclinical findings and clinical implications. Rev. Cancer 1806, 172-182. doi: 10.1016/j.bbcan.2010.07.004.
85. Kraemer, K. H., Lee, M. M., and Scotto, J. (1987). Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch. Dermatol. 123, 241-250. doi: 10.1001/archderm.1987.01660260111026.
86. Krasikova, Y. S., Rechkunova, N. I., Maltseva, E. A., Petruseva, I. O., and Lavrik, O. I. (2010). Localization of xeroderma pigmentosum group A protein and replication protein A on damaged DNA in nucleotide excision repair. Nucleic Acids Res. 38, 8083-8094. doi: 10.1093/nar/gkq649.
87. Kratz, K., Schöpf, B., Kaden, S., Sendoel, A., Eberhard, R., Lademann, C., et al. (2010). Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents. Cell 142, 77-88. doi: 10.1016/j.cell.2010.06.022.
88. Krumbhaar, E. B., and Krumbhaar, H. D. (1919). The blood and bone marrow in yelloe cross gas (Mustard Gas) poisoning: changes produced in the Bone Marrow of Fatal Cases. J. Med. Res. 40, 497-508.
89. Larrea, A. A., Lujan, S. A., Nick McElhinny, S. A., Mieczkowski, P. A., Resnick, M. A., Gordenin, D. A., et al. (2010). Genome-wide model for the normal eukaryotic DNA replication fork. Proc. Natl. Acad. Sci. U.S.A. 107, 17674-17679. doi: 10.1073/pnas.1010178107.
90. Lavin, M. F., Birrell, G., Chen, P., Kozlov, S., Scott, S., and Gueven, N. (2005). ATM signaling and genomic stability in response to DNA damage. Mutat. Res. 569, 123-132. doi: 10.1016/j.mrfmmm.2004.04.020.
91. Lebwohl, D., and Canetta, R. (1998). Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur. J. Cancer 34, 1522-1534. doi: 10.1016/S0959-8049(98)00224-X.
92. Lee, J.-H. (2004). Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science 304, 93-96. doi: 10.1126/science.1091496.
93. Lehmann, A. R., Kirk-Bell, S., Arlett, C. F., Paterson, M. C., Lohman, P. H., De Weerd-Kastelein, E. A., et al. (1975). Xeroderma pigmentosum cells with normal levels of excision repair have a defect in DNA synthesis after UV-irradiation. Proc. Natl. Acad. Sci. U.S.A. 72, 219-223. doi: 10.1073/pnas.72.1.219.
94. Leibeling, D., Laspe, P., and Emmert, S. (2006). Nucleotide excision repair and cancer. J. Mol. Hist. 37, 225-238. doi: 10.1007/s10735-006-9041-x.
95. Li, M., Lu, L.-Y., Yang, C.-Y., Wang, S., and Yu, X. (2013). The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response. Genes Dev. 27, 1752-1768. doi: 10.1101/gad.226357.113.
96. Lindahl, T., and Barnes, D. E. (2000). Repair of endogenous DNA damage. Cold Spring Harb. Symp. Quant. Biol. 65, 127-133. doi: 10.1101/sqb.2000.65.127.
97. Liu, J., Doty, T., Gibson, B., and Heyer, W.-D. (2010). Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat. Struct. Mol. Biol. 17, 1260-1262. doi: 10.1038/nsmb.1904.
98. Liu, L., and Gerson, S. L. (2004). Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr. Opin. Investig. Drugs 5, 623-627.
99. Lomax, M. E., Folkes, L. K., and O'Neill, P. (2013). Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin. Oncol. 25, 578-585. doi: 10.1016/j.clon.2013.06.007.
100. Lumsden, J. M. (2004). Immunoglobulin class switch recombination is impaired in atm-deficient mice. J. Exp. Med. 200, 1111-1121. doi: 10.1084/jem.20041074.
101. Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., et al. (2007). ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-1166. doi: 10.1126/science.1140321.
102. McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Bialkowska, A., Swift, S., et al. (2006). Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115. doi: 10.1158/0008-5472.CAN-06-0140.
103. McKay, B. C., Becerril, C., and Ljungman, M. (2001). P53 plays a protective role against UV-and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Oncogene 20, 6805-6808. doi: 10.1038/sj.onc.1204901.
104. Moeller, B. J., Yordy, J. S., Williams, M. D., Giri, U., Raju, U., Molkentine, D. P., et al. (2011). DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin. Cancer Res. 17, 2035-2043. doi: 10.1158/1078-0432.CCR-10-2641.
105. Monteiro, A. N. (2000). BRCA1: exploring the links to transcription. Trends Biochem. Sci. 25, 469-474. doi: 10.1016/S0968-0004(00)01632-7.
106. More, S. S., Akil, O., Ianculescu, A. G., Geier, E. G., Lustig, L. R., and Giacomini, K. M. (2010). Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J. Neurosci. 30, 9500-9509. doi: 10.1523/JNEUROSCI.1544-10.2010.
107. Moser, J., Kool, H., Giakzidis, I., Caldecott, K., Mullenders, L. H. F., and Fousteri, M. I. (2007). Sealing of chromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase IIIa in a cell-cycle-specific manner. Mol. Cell 27, 311-323. doi: 10.1016/j.molcel.2007.06.014.
108. Natale, V. (2011). A comprehensive description of the severity groups in Cockayne syndrome. Am. J. Med. Genet. 155A, 1081-1095. doi: 10.1002/ajmg.a.33933.
109. Nijman, S. M. B., Huang, T. T., Dirac, A. M. G., Brummelkamp, T. R., Kerkhoven, R. M., D'Andrea, A. D., et al. (2005). The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 17, 331-339. doi: 10.1016/j.molcel.2005.01.008.
110. O'Driscoll, M., Ruiz-Perez, V. L., Woods, C. G., Jeggo, P. A., and Goodship, J. A. (2003). A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat. Genet. 33, 497-501. doi: 10.1038/ng1129.
111. Pabla, N., Huang, S., Mi, Q.-S., Daniel, R., and Dong, Z. (2008). ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J. Biol. Chem. 283, 6572-6583. doi: 10.1074/jbc.M707568200.
112. Pace, P., Mosedale, G., Hodskinson, M. R., Rosado, I. V., Sivasubramaniam, M., and Patel, K. J. (2010). Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway. Science 329, 219-223. doi: 10.1126/science.1192277.
113. Paglia, L. L., Laugé, A., Weber, J., Champ, J., Cavaciuti, E., Russo, A., et al. (2009). ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy. Breast Cancer Res. Treat. 119, 443-452. doi: 10.1007/s10549-009-0396-z.
114. Park, G. Y., Wilson, J. J., Song, Y., and Lippard, S. J. (2012). Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc. Natl. Acad. Sci. U.S.A. 109, 11987-11992. doi: 10.1073/pnas.1207670109.
115. Pegg, A. E., Dolan, M. E., and Moschel, R. C. (1994). Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid. Res. Mol. Biol. 51, 167-223. doi: 10.1016/S0079-6603(08)60879-X.
116. Plunkett, W., Huang, P., Xu, Y. Z., Heinemann, V., Grunewald, R., and Gandhi, V. (1995). Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol. 22, 3-10.
117. Puyo, S., Montaudon, D., and Pourquier, P. (2014). From old alkylating agents to new minor groove binders. Crit. Rev. Oncol. Hematol. 89, 43-61. doi: 10.1016/j.critrevonc.2013.07.006.
118. Ralhan, R., and Kaur, J. (2007). Alkylating agents and cancer therapy. Expert Opin. Ther. Patents 17, 1061-1075. doi: 10.1517/13543776.17.9.1061.
119. Raymond, E., Faivre, S., Chaney, S., Woynarowski, J., and Cvitkovic, E. (2002). Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. 1, 227-235.
120. Reinhardt, H., Jiang, H., Hemann, M., and Yaffe, M. (2009). Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 8, 3112-3119. doi: 10.4161/cc.8.19.9626.
121. Rosenberg, B., Van Camp, L., and Krigas, T. (1965). Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698-699. doi: 10.1038/205698a0.
122. Rosenberg, B., Van Camp, L., Trosko, J. E., and Mansour, V. H. (1969). Platinum compounds: a new class of potent antitumour agents. Nature 222, 385-386. doi: 10.1038/222385a0.
123. Rosenberg, P. S., Tamary, H., and Alter, B. P. (2011). How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel. Am. J. Med. Genet. A 155A, 1877-1883. doi: 10.1002/ajmg.a.34087.
124. Ross, D. D., Chen, S. R., and Cuddy, D. P. (1990). Effects of 1-β-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution. Cancer Res. 50, 2658-2666.
125. Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., and Poirier, G. G. (2010). PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10, 293-301. doi: 10.1038/nrc2812.
126. Roy, R., Chun, J., and Powell, S. N. (2011). BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer 12, 68-78. doi: 10.1038/nrc3181.
127. Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., and Linn, S. (2004). Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73, 39-85. doi: 10.1146/annurev.biochem.73.011303.073723.
128. Schlacher, K., Wu, H., and Jasin, M. (2012). A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 22, 106-116. doi: 10.1016/j.ccr.2012.05.015.
129. Schumacher, B., Garinis, G. A., and Hoeijmakers, J. H. J. (2008). Age to survive: DNA damage and aging. Trends Genet. 24, 77-85. doi: 10.1016/j.tig.2007.11.004.
130. Schwab, R. A., Blackford, A. N., and Niedzwiedz, W. (2010). ATR activation and replication fork restart are defective in FANCM-deficient cells. EMBO J. 29, 806-818. doi: 10.1038/emboj.2009.385.
131. Shiloh, Y. (2003). ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 3, 155-168. doi: 10.1038/nrc1011.
132. Singh, T. R., Saro, D., Ali, A. M., Zheng, X.-F., Du, C.-H., Killen, M. W., et al. (2010). MHF1-MHF2, a histone-fold-containing protein complex, participates in the Fanconi anemia pathway via FANCM. Mol. Cell 37, 879-886. doi: 10.1016/j.molcel.2010.01.036.
133. Smits, V. A. J., Warmerdam, D. O., Martin, Y., and Freire, R. (2010). Mechanisms of ATR-mediated checkpoint signalling. Front. Biosci. (Landmark Ed.) 15, 840-853. doi: 10.2741/3649.
134. Smogorzewska, A., Matsuoka, S., Vinciguerra, P., McDonald, E. R., Hurov, K. E., Luo, J., et al. (2007). Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 129, 289-301. doi: 10.1016/j.cell.2007.03.009.
135. Song, I.-S., Savaraj, N., Siddik, Z. H., Liu, P., Wei, Y., Wu, C. J., et al. (2004). Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol. Cancer Ther. 3, 1543-1549.
136. Stone, M. P., Cho, Y.-J., Huang, H., Kim, H.-Y., Kozekov, I. D., Kozekova, A., et al. (2008). Interstrand DNA cross-links induced by a,β-unsaturated aldehydes derived from lipid peroxidation and environmental sources. Acc. Chem. Res. 41, 793-804. doi: 10.1021/ar700246x.
137. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996. doi: 10.1056/NEJMoa043330.
138. Sugasawa, K., Okuda, Y., Saijo, M., Nishi, R., Matsuda, N., Chu, G., et al. (2005). UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex. Cell 121, 387-400. doi: 10.1016/j.cell.2005.02.035.
139. Sung, P., and Klein, H. (2006). Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat. Rev. Mol. Cell Biol. 7, 739-750. doi: 10.1038/nrm2008.
140. Suzuki, A., de la Pompa, J. L., Hakem, R., Elia, A., Yoshida, R., Mo, R., et al. (1997). Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev. 11, 1242-1252. doi: 10.1101/gad.11.10.1242.
141. Swords, R., and Giles, F. (2007). Troxacitabine in acute leukemia. Hematology 12, 219-227. doi: 10.1080/10245330701406881.
142. Tanaka, A., Weinel, S., Nagy, N., O'Driscoll, M., Lai-Cheong, J. E., Kulp-Shorten, C. L., et al. (2012). Germline mutation in ATR in autosomal-dominant oropharyngeal cancer syndrome. Am. J. Hum. Genet. 90, 511-517. doi: 10.1016/j.ajhg.2012.01.007.
143. Tangutoori, S., Baldwin, P., and Sridhar, S. (2015). PARP inhibitors: a new era of targeted therapy. Maturitas doi: 10.1016/j.maturitas.2015.01.015 [Epub ahead of print].
144. Taniguchi, T., Garcia-Higuera, I., Andreassen, P. R., Gregory, R. C., Grompe, M., and D'Andrea, A. D. (2002). S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1, and RAD51. Blood 100, 2414-2420. doi: 10.1182/blood-2002-01-0278.
145. Thompson, D., Duedal, S., Kirner, J., McGuffog, L., Last, J., Reiman, A., et al. (2005). Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl. Cancer Inst. 97, 813-822. doi: 10.1093/jnci/dji141.
146. Thoms, J., and Bristow, R. G. (2010). DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin. Radiat. Oncol. 20, 217-222. doi: 10.1016/j.semradonc.2010.06.003.
147. Thorslund, T., McIlwraith, M. J., Compton, S. A., Lekomtsev, S., Petronczki, M., Griffith, J. D., et al. (2010). The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA. Nat. Struct. Mol. Biol. 17, 1263-1265. doi: 10.1038/nsmb.1905.
148. Topping, R. P., Wilkinson, J. C., and Scarpinato, K. D. (2009). Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling. J. Biol. Chem. 284, 14029-14039. doi: 10.1074/jbc.M809303200.
149. van der Heijden, M. S., Brody, J. R., Gallmeier, E., Cunningham, S. C., Dezentje, D. A., Shen, D., et al. (2004). Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am. J. Pathol. 165, 651-657. doi: 10.1016/S0002-9440(10)63329-9.
150. van der Pluijm, I., Garinis, G. A., Brandt, R. M. C., Gorgels, T. G. M. F., Wijnhoven, S. W., Diderich, K. E. M., et al. (2007). Impaired genome maintenance suppresses the growth hormone-insulin-like growth factor 1 axis in mice with Cockayne syndrome. PLoS Biol. 5:e2. doi: 10.1371/journal.pbio.0050002.
151. van Maanen, M. J., Smeets, C. J. M., and Beijnen, J. H. (2000). Chemistry, pharmacology and pharmacokinetics of N,N',N'-triethylenethiophosphoramide (ThioTEPA). Cancer Treat. Rev. 26, 257-268. doi: 10.1053/ctrv.2000.0170.
152. van Moorsel, C. J., Pinedo, H. M., Smid, K., Comijn, E. M., Voorn, D. A., Veerman, G., et al. (2000). Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. Eur. J. Cancer 36, 2420-2429. doi: 10.1016/S0959-8049(00)00345-2.
153. Venema, J., Van Hoffen, A., Karcagi, V., Natarajan, A. T., van Zeeland, A. A., and Mullenders, L. H. (1991). Xeroderma pigmentosum complementation group C cells remove pyrimidine dimers selectively from the transcribed strand of active genes. Mol. Cell. Biol. 11, 4128-4134.
154. Venkitaraman, A. R. (2009). Linking the cellular functions of BRCAGenes to cancer pathogenesis and treatment. Annu. Rev. Pathol. Mech. Dis. 4, 461-487. doi: 10.1146/annurev.pathol.3.121806.151422.
155. Wagner, R., and Meselson, M. (1976). Repair tracts in mismatched DNA heteroduplexes. Proc. Natl. Acad. Sc. U.S.A. 73, 4135-4139. doi: 10.1073/pnas.73.11.4135.
156. Walden, H., and Deans, A. J. (2014). The fanconi anemia DNA repair pathway: structural and functional insights into a complex disorder. Annu. Rev. Biophys. 43, 257-278. doi: 10.1146/annurev-biophys-051013-022737.
157. Wallace, S. S. (2002). Biological consequences of free radical-damaged DNA bases. Free Radic. Biol. Med. 33, 1-14. doi: 10.1016/S0891-5849(02)00827-4.
158. Wallner, P. E. (2006). "Naked" radiopharmaceuticals. Int. J. Radiat. Oncol. Biol. Phys. 66, S60-S61. doi: 10.1016/j.ijrobp.2006.04.056.
159. Wang, J., Lohman, G. J. S., and Stubbe, J. (2007). Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases. Proc. Natl. Acad. Sci. U.S.A. 104, 14324-14329. doi: 10.1073/pnas.0706803104.
160. Wang, Y., Liu, X., Matsuda, A., and Plunkett, W. (2008). Repair of 2'-C-Cyano-2'-Deoxy-1-β-D-arabino-Pentofuranosylcytosine-Induced DNA single-strand breaks by transcription-coupled nucleotide excision repair. Cancer Res. 68, 3881-3889. doi: 10.1158/0008-5472.CAN-07-6885.
161. Welsh, C., Day, R., McGurk, C., Masters, J. R. W., Wood, R. D., and Köberle, B. (2004). Reduced levels of XPA, ERCC1, and XPF DNA repair proteins in testis tumor cell lines. Int. J. Cancer 110, 352-361. doi: 10.1002/ijc.20134.
162. Wolters, S., Ermolaeva, M. A., Bickel, J. S., Fingerhut, J. M., Khanikar, J., Chan, R. C., et al. (2014). Loss of Caenorhabditis elegans BRCA1 promotes genome stability during replication in smc-5 mutants. Genetics 196, 985-999. doi: 10.1534/genetics.113.158295.
163. Wu, J., Zhang, X., Zhang, L., Wu, C.-Y., Rezaeian, A. H., Chan, C.-H., et al. (2012). Skp2 E3 ligase integrates ATM activation and homologous recombination repair by ubiquitinating NBS1. Mol. Cell 46, 351-361. doi: 10.1016/j.molcel.2012.02.018.
164. Wu, L. C., Wang, Z. W., Tsan, J. T., Spillman, M. A., Phung, A., Xu, X. L., et al. (1996). Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet. 14, 430-440. doi: 10.1038/ng1296-430.
165. Wu, L., and Hickson, I. D. (2003). The Bloom's syndrome helicase suppresses crossing over during homologous recombination. Nature 426, 870-874. doi: 10.1038/nature02253.
166. Ye, Q., Hu, Y. F., Zhong, H., Nye, A. C., Belmont, A. S., and Li, R. (2001). BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations. J. Cell Biol. 155, 911-921. doi: 10.1083/jcb.200108049.
167. Zhang, F., Fan, Q., Ren, K., and Andreassen, P. R. (2009a). PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol. Cancer Res. 7, 1110-1118. doi: 10.1158/1541-7786.MCR-09-0123.
168. Zhang, J., Stevens, M. F. G., Laughton, C. A., Madhusudan, S., and Bradshaw, T. D. (2009b). Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 78, 103-114. doi: 10.1159/000306139.
169. Zhang, J., Visser, F., King, K. M., Baldwin, S. A., Young, J. D., and Cass, C. E. (2007). The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev. 26, 85-110. doi: 10.1007/s10555-007-9044-4.
170. Zhang, Y., Yuan, F., Presnell, S. R., Tian, K., Gao, Y., Tomkinson, A. E., et al. (2005). Reconstitution of 5'-Directed human mismatch repair in a purified system. Cell 122, 693-705. doi: 10.1016/j.cell.2005.06.027.
171. Zou, L., and Elledge, S. J. (2003). Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300, 1542-1548. doi: 10.1126/science.1083430.